Rahul Raghu, MD
Glaucoma Specialist · San Ramon, CANPI 1689025512
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 38.7% of the total. Reporting peaked in 2023 at $1,684 and has fallen 51.8% since, to $812 in 2025.
Across 150 payments — averaging $34.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$694
- Carl Zeiss Meditec USA, Inc.$396
- Bausch & Lomb Americas Inc.$315
- Sun Pharmaceutical Industries Inc.$261
- Glaukos Corporation$228
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,14399%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $2,001 |
| Alcon | 13 | $694 |
| Carl Zeiss Meditec USA, Inc. | 6 | $396 |
| Bausch & Lomb Americas Inc. | 11 | $315 |
| Sun Pharmaceutical Industries Inc. | 8 | $261 |
| Glaukos Corporation | 3 | $228 |
| Oyster Point Pharma, Inc. | 5 | $199 |
| Mallinckrodt Hospital Products Inc. | 8 | $161 |
| Sight Sciences, Inc. | 4 | $138 |
| Thea Pharma Inc. | 7 | $135 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $134 |
| Regeneron | 1 | $130 |
| Aerie Pharmaceuticals, Inc. | 4 | $114 |
| Harrow Eye, LLC | 1 | $64 |
| Carl Zeiss Meditec, Inc. | 2 | $43 |
| Biotissue Holdings Inc. | 1 | $33 |
| Amgen | 1 | $28 |
| Ivantis, Inc | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Dompe US, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
| Tarsus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$330
- ORA$263
- Rocklatan$244
- EYLEA$130
- TYRVAYA$125
- CEQUA$125
- Rhopressa$122
- Voyager DSLT$122
- DURYSTA$121
- MIEBO$121
- OZURDEX$111
- CATALYS SYSTEM$110
How this compares
$5,169 in reported general payments places this provider in the 55th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 70 | $35,956 |
| LumiganBimatoprost | 69 | $34,707 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $7,779 |
| ProlensaBromfenac Sodium | 19 | $7,122 |
| Latanoprost | 637 | $6,320 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $5,953 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 41 | $5,746 |
| Methazolamide | 21 | $5,050 |
| IyuzehLatanoprost/Pf | 11 | $4,322 |
| Prednisolone Acetate | 67 | $4,008 |
| Lotemax SmLoteprednol Etabonate | 15 | $3,631 |
| Timolol Maleate | 229 | $2,541 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $2,469 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 145 | $2,291 |
| Brimonidine Tartrate | 99 | $1,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $2,001 | $40,66086 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $114 | $35,95670 claims |
| AlconSimbrinza | $694 | $7,77939 claims |
| Thea Pharma Inc.Iyuzeh | $135 | $4,32211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in San Ramon
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.